Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 7% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
3Q Revenues: $20.3 billion (+4%)
3Q Earnings: $3.9 billion (+5%)
YTD Revenues: $61.2 billion (+9%)
YTD Earnings: $12.3 billion (+2%)
Comments: Pharmaceutical sales were $10.3 billion in the quarter, up 7%.  Domestic sales increased 5%,  and international sales increased 10%, which reflected an operational increase of 13% and a negative currency impact of 4%. Remicade sales were down 16% to $1.4 billion, due to competition. Simponi sales were up 13% to $536 million. Stelara sales were $1.3 billion, up 17%. Xarelto sales were $612 million in the quarter, down 4%. Zytiga sales were $958 million, up 43%. Imbruvica sales were $705 million, up 38%. Darzalex sales were $498 million, up 57%. Invega Sustenna sales were $749 million, up 17%. Worldwide Consumer sales were $3.4 billion in the quarter, up 2%. Medical Device sales were $6.6 billion in the quarter, down .2%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters